Loading...
•
Sep 30, 2024
Regulus Therapeutics Q3 2024 Earnings Report
Regulus Therapeutics reported financial results for Q3 2024 and provided a corporate update.
Key Takeaways
Regulus Therapeutics reported a net loss of $14.1 million for the third quarter ended September 30, 2024. The company's cash, cash equivalents, and investments totaled $87.3 million as of September 30, 2024, providing a cash runway into H1 2026. Enrollment was completed in the fourth cohort of the Phase 1b MAD clinical trial of RGLS8429 for ADPKD, with topline data expected in early 2025.
Completed enrollment in the fourth cohort of the Phase 1b MAD clinical trial of RGLS8429 for the treatment of ADPKD.
Presented a poster highlighting data from the ongoing MAD study of RGLS8429 in ADPKD at ASN Kidney Week.
On track for an End-of-Phase 1 meeting by year-end.
Ended third quarter 2024 with cash, cash equivalents, and investments of $87.3 million; Cash runway into H1 2026.
Forward Guidance
The company expects to share preliminary topline data from a substantial number of patients from the fourth cohort in the Phase 1b MAD study of RGLS8429 in ADPKD in early 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...